

DMD # 40378

TITLE PAGE

Independent and combined effects of ethanol self-administration and nicotine treatment on hepatic CYP2E1 in African Green monkeys

C.S. Ferguson, S. Miksys, R. Palmour, R.F. Tyndale.

Centre for Addiction and Mental Health and Departments of Psychiatry, Pharmacology and Toxicology, University of Toronto, Canada (CSF, SM, RFS); Department of Psychiatry, McGill University, Montreal, Canada (RP)

DMD # 40378

RUNNING TITLE PAGE

Running Title: Ethanol and Nicotine Induce Hepatic CYP2E1

Correspondence to:

Dr. Rachel F. Tyndale,

Department of Pharmacology and Toxicology

Rm 4326, 1 King's College Circle,

Toronto ON., Canada M5S 1A8

Phone: [416] 978-6374

Fax: [416] 978-6395

Email: r.tyndale@utoronto.ca

The number of text pages is:

The number of figures are: 7

The number of References are: 40

The number of words in the Abstract are: 250

The number of words in the Introduction are: 622

The number of words in the Discussion are: 1431

Abbreviations: AGM; African green monkeys, ADH; alcohol dehydrogenase, ANOVA; analysis of variance, BEL; blood ethanol levels, CZN; Chlorzoxazone, CYP2E1; Cytochrome P450 2E1, 6OHCZN; 6-hydroxychlorzoxazone

DMD # 40378

ABSTRACT

Cytochrome P450 2E1 (CYP2E1) metabolizes ethanol and also bioactivates many toxins and procarcinogens. Elevated levels of hepatic CYP2E1 are associated with an increased susceptibility to chemical toxicity and carcinogenesis. This study investigated the induction of hepatic CYP2E1 by ethanol and nicotine, alone and in combination, in a non-human primate model. Monkeys self-administered ethanol and nicotine was administered as subcutaneous injections (0.5 mg/kg bid), alone and in combination compared to control animals (4 groups, N=10/group). Chlorzoxazone was used as a probe drug to phenotype *in vivo* CYP2E1 activity before and after chronic ethanol and/or nicotine exposure. CYP2E1 protein levels and *in vitro* chlorzoxazone metabolism were assessed in liver microsomes. Average daily ethanol consumption was ≈ 3.0 g/kg (blood ethanol levels ≈ 24 mmol/L) and was unaffected by nicotine treatment. Ethanol self-administration and nicotine treatment, alone and in combination, significantly increased *in vivo* CZN disposition compared to control animals. The effect of ethanol was only observed at higher levels of intake. Ethanol and nicotine increased CYP2E1 protein levels and *in vitro* CZN metabolism, with combined exposure to both drugs resulting in the greatest increase. The effect of ethanol was also dependent on level of intake. Chronic exposure to ethanol and nicotine induced hepatic CYP2E1 activity and protein levels, particularly when both drugs were used in combination and when ethanol intake was high. These results have important implications for public health, given the association between elevated CYP2E1 and disease, and the large proportion of individuals who are exposed to ethanol and nicotine, often in combination.

DMD # 40378

INTRODUCTION

Cytochrome P450 2E1 (CYP2E1) is a drug metabolizing enzyme that is responsible for the biotransformation of numerous low-molecular weight compounds, including ethanol, several commonly used industrial solvents, environmental pollutants, and various clinical drugs (Lieber, 1997). Many of these substrates are pro-carcinogens or cytotoxins that are bioactivated by CYP2E1. CYP2E1 is also known to generate high levels of reactive oxygen species that can cause cell damage via lipid peroxidation and DNA strand breaks (Caro and Cederbaum, 2004).

Elevated levels of CYP2E1 are associated with increased susceptibility to chemical toxicity and carcinogenesis. Several polymorphisms have been identified in the human *CYP2E1* gene. Individuals with the *CYP2E1* RsaI c2 allele, associated with increased CYP2E1 transcriptional activity (Hayashi et al., 1991), are more susceptible to toxicity from industrial chemicals bioactivated by CYP2E1 such as vinyl chloride (Wang et al., 2010) and n-hexane (Zhang et al., 2006). This and other *CYP2E1* genetic variants have been associated with increased risk for hepatocellular (Munaka et al., 2003), colorectal (Morita et al., 2009) and esophageal cancer (Liu et al., 2007).

Hepatic CYP2E1 can be induced by a variety of compounds, many of which are substrates. Ethanol is an inducer of hepatic CYP2E1 protein and activity in humans and monkeys (Lieber, 1997; Ivester et al., 2007). Smoking increases CYP2E1 activity in humans (Benowitz et al., 2003) and chronic nicotine treatment increases hepatic CYP2E1 protein levels and activity in monkeys (Lee et al., 2006b).

Approximately 90% of smokers also consume alcohol (Shiffman S., 1995), yet little is known about the combined effects of ethanol and nicotine on hepatic CYP2E1 levels. It was previously shown that rats exposed to both ethanol and nicotine had significantly greater levels

DMD # 40378

of hepatic CYP2E1 protein compared rats exposed to either drug alone (Yue et al., 2009). This enhancement of CYP2E1 protein was partially attributed to a nicotine-stimulated increase in ethanol consumption. There was no indication as to how the observed increases in CYP2E1 protein levels would affect *in vitro* and *in vivo* CYP2E1 activity. Understanding the impact of ethanol and nicotine on CYP2E1-mediated metabolism is crucial, given the large proportion of the population that is exposed to both drugs and the potential for elevated CYP2E1 to cause toxicity and disease.

The African green monkey (AGM) is established as an excellent animal model of human CYP2E1 expression and activity (Lee et al., 2006b). Chlorzoxazone (CZN), a clinically used muscle relaxant that is metabolized by CYP2E1 to 6-hydroxychlorzoxazone (6OHCZN), is a validated probe drug for the measurement of CYP2E1 activity in both humans and monkeys (Ernstgard et al., 2004; Lee et al., 2006b). As in other species, CZN-6-hydroxylation in monkey liver microsomes can be inhibited by anti-CYP2E1 antibodies and selective chemical inhibitors of CYP2E1 providing evidence that CYP2E1 is the primary enzyme involved in the 6-hydroxylation of CZN (Amato et al., 1998). AGMs are also useful in modeling human alcohol consumption. These monkeys will voluntarily self-administer alcohol at levels comparable to human consumption and are therefore routinely used in alcohol research (Palmour et al., 1997).

We investigated the independent and combined effects of ethanol self-administration and nicotine treatment on *in vivo* CZN disposition, hepatic CYP2E1 protein levels and *in vitro* CZN metabolism. We hypothesized that ethanol and nicotine would independently induce CYP2E1 levels resulting in increased CZN clearance *in vivo* and *in vitro* CZN metabolism. In addition, combined ethanol and nicotine exposure was hypothesized to result in greater induction of CYP2E1 protein and *in vitro* CZN activity compared to either drug alone, due to both the direct

DMD # 40378

effects of the inducers and a nicotine-mediated increase in alcohol consumption. The induction of CYP2E1 by ethanol is dose-dependent in humans (Millonig et al., 2011), therefore we also investigated if the effects of ethanol were dependent on the level of alcohol intake.

DMD # 40378

METHODS

Materials. Chlorzoxazone (CZN), and 2-benzoxazolinone were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). All other chemicals were obtained from standard commercial sources. Protein estimation was performed with dye reagent purchased from Bio-Rad Laboratories (Hercules, CA). Prestained molecular weight protein markers were purchased from MBI Fermentas (Flamborough, ON, Canada). Hybond nitrocellulose membrane was purchased from Amersham Biosciences (Toronto, ON, Canada). Human cDNA expressed CYP2E1, CYP2A6, CYP2A1, CYP2A2, CYP2D6, CYP3A4 and CYP2B6 were purchased from BD Biosciences (Franklin Lakes, NJ). Polyclonal anti-rat CYP2E1 antibody was purchased from Fitzgerald Industries (Acton, MA). Horseradish peroxidase-conjugated anti-sheep secondary antibody was purchased from Millipore. (Billerica, MA). Chemiluminescent substrate was purchased from Pierce Chemical Company (Rockford, IL). Autoradiographic film was purchased from Ultident (St. Laurent, PQ, Canada).

Animals. Adult male African green monkeys (vervets, *C. aethiops*) were housed outdoors in social groups at Caribbean Primates Ltd (St Kitts). They were acquired from a large, isolated, and non-endangered Caribbean population (Palmour et al., 1997). Monkeys were given standard rations of Purina monkey chow supplemented with fresh fruit and vegetables twice a day and were allowed to feed ad libitum. Drinking water was also available ad libitum

Drug Treatment. The study timeline is shown in Figure 1. The first 14 days of the study consisted of an ethanol preference screening phase, where monkeys were given access to 10% v/v alcohol in 0.5% w/v sucrose solution for 4 hours per day. Forty monkeys that voluntarily

DMD # 40378

consumed more than 1g ethanol/kg/day were selected and randomized into four groups based on daily ethanol consumption (n=10 per group). The following 14 days (day 15-28) consisted of a washout period, where monkeys had no exposure to ethanol or nicotine. During the second phase of the study, from day 29-42, monkeys in the ethanol-only (group 2) and ethanol + nicotine (group 4) groups were allowed to self-administer 10% alcohol in 0.5% sucrose solution for 4 hours a day while the other groups (1 and 3) consumed 0.5% sucrose solution on the same schedule. During the third phase of the study, from day 43-63, in addition to alcohol (or sucrose), monkeys in the nicotine-only (group 3) and ethanol + nicotine (group 4) were given s.c injections of nicotine bitartrate (milligram base in saline, pH 7.0) twice daily at a dose of 0.05 mg/kg on day 43, 0.1 mg/kg on day 44, 0.25 mg/kg on day 45, and 0.5 mg/kg for subsequent days. The first injection was given 30 min prior to the alcohol (or sucrose) access period. The second injection was given 10 hours later. Monkeys in ethanol-only (group 2) and control (group 1) groups were given saline injections (as a vehicle control for nicotine bitartrate) on the same schedule. On day 50, nicotine treatment and alcohol access was suspended in order to conduct pharmacokinetic testing. Monkeys received 7 mg/kg CZN intragastrically under ketamine anesthesia, and blood samples were drawn at t-10 min (10 minutes before CZN administration), 10, 20, 30, 60, 120, 240, and 360 min after CZN administration. Blood samples (2 ml) were drawn immediately after the alcohol access period on days 38 and 59 to determine blood ethanol levels. All blood samples were centrifuged and the plasma removed and frozen for subsequent drug analyses. A commercial enzymatic assay kit (Sigma Diagnostics, St Louis, MO) was used to determine plasma blood levels of ethanol. Body weights at the start of the study (average = 5.9 kg \pm 0.5) were not significantly different from body weights at sacrifice (average = 5.7 kg \pm 0.5) (paired t-test, $p>0.5$). There was no significant differences in body weights between groups at the

DMD # 40378

start of the study (one way ANOVA, $F(3, 36) = 0.3784$, $p > 0.05$) or at sacrifice (one way ANOVA, $F(3, 36) = 1.860$, $p > 0.05$). Animals were sacrificed by exsanguination via the femoral artery under ketamine anesthesia and livers were immediately dissected and flash-frozen in liquid nitrogen and stored at -80°C until further use. Upon visual inspection of the livers, there were no apparent signs of injury or cirrhosis. The experimental protocol was reviewed and approved by the Institutional Review Board of Behavioral Sciences Foundation and the University of Toronto Animal Care Committee. All the procedures were conducted in accordance with the guidelines of the Canadian Council on Animal Care.

In Vivo CZN Plasma Assessments. Plasma CZN levels were assayed based on the methods in Howard et al. (2001). Briefly, plasma was centrifuged at $3000g$ for 10 min, after which $100\ \mu\text{l}$ of the supernatant was removed and incubated with β -glucuronidase ($10\ \text{mg/ml}$, $50\ \mu\text{l}$) overnight at 37°C . Following incubation, internal standard of 2-benzoxazolinone ($2.0\ \text{mM}$, $25\ \mu\text{l}$), 10% perchloric acid ($120\ \mu\text{l}$) and ethyl acetate/hexane ($3\ \text{ml}$) were added, the sample was shaken for 30 min, centrifuged at $3500g$ for 15 min, and the organic phase was evaporated to dryness at 37°C . The sample was reconstituted into $110\ \mu\text{l}$ of mobile phase consisting of $50\ \text{mM}$ ammonium acetate (adjusted to pH to 4.0 with $1\ \text{M}$ glacial acetic acid)/acetonitrile (65:35). CZN was measured by high-performance liquid chromatography with UV detection at $287\ \text{nm}$. An Agilent Zorbax SB-C18 column ($5\ \mu\text{m}$, $4.6 \times 250\ \text{mm}$) (Agilent Technologies, Palo Alto, CA) was used to separate CZN, and 2-benzoxazolinone using a flow rate of $0.7\ \text{ml/min}$. The retention times for CZN and 2-benzoxazolinone were 18.5 and 10.1 min, respectively.

DMD # 40378

Microsomal Membrane Preparation. Monkey liver tissue was homogenized in 100 mM Tris, 0.1 mM EDTA, 0.1 mM DDT, and 0.32 M sucrose (pH 7.4) for immunoblotting, or in 1.15% w/v KCl for *in vitro* metabolism assessments and then centrifuged at 12,500g for 30 min at 4°C. The supernatant was then centrifuged at 110,000g for 90 min at 4°C, and the pellet was resuspended in 100 mM Tris, 0.1 mM EDTA, 0.1 mM DDT, 1.15% w/v KCl, and 20% v/v glycerol for immunoblotting or 1.15% w/v KCl for *in vitro* metabolism assays. The protein content of liver microsomes was assayed with the Bradford technique using a Bio-Rad Protein Assay kit. Microsomes were stored at –80°C.

In Vitro CZN and 6OHCZN Assessments. CZN 6-hydroxylation was assayed according to the protocol established by Leclercq et al., in which the protein concentration and incubation times were optimized for linear formation of 6OHCZN (Leclercq et al., 1998). Monkey hepatic microsomal protein (0.4 mg) was mixed with 0.1 M Tris buffer at pH 7.6, 10 mM magnesium chloride, 5 mM NADPH and 950 µM CZN to a final volume of 500 µl. The reaction mixture was incubated for 20 min at 37°C. Zinc sulfate (15% w/v, 0.2 ml) was added to stop the reaction, and 6.4 µg of the internal standard, 2-benzoxazolinone in Tris buffer, was added per reaction. Following centrifugation for 10 min at 12,700g, the supernatant was injected onto an Agilent Zorbax SB-C18 column (5 µm, 4.6 x 250 mm) (Agilent Technologies, Palo Alto, CA) with UV detection at 287 nm. The mobile phase consisted of 50 mM ammonium acetate (adjusted to pH to 4.0 with 1 M glacial acetic acid)/acetonitrile (65:35) with a flow rate of 0.7 ml/min. The retention times for CZN, 6OHCZN, and 2-benzoxazolinone were 18.5, 7.5, and 10.1 min, respectively. The absolute and relative recoveries of 6OHCZN were 90.4% and 99.4% respectively.

DMD # 40378

Immunoblotting. Monkey liver microsomal protein was serially diluted to generate a standard curve and to establish the linear detection range for the immunoblotting assays. To determine cross-reactivity of the primary antibodies, cDNA-expressed human CYP2E1, CYP2A6, CYP1A1, CYP2A2, CYP2D6, CYP3A4 and CYP2B6 were used as positive or negative controls.

Liver microsomal proteins (4 ug) were separated by SDS-polyacrylamide gel electrophoresis (4% stacking and 8% separating gels), and then transferred overnight onto nitrocellulose membranes. Gels were stained with Coomassie blue R-250 to ensure equal loading of protein among lanes. To detect hepatic CYP2E1, the membranes were first blocked with 1% skim milk in 50 mM Tris-buffered saline (TBS) containing 0.1% w/v bovine serum albumin, 0.1% v/v Triton X-100 for 1 hr. Membranes were then incubated with anti-CYP2E1 antibody diluted 1:1000 for 2 h, followed by three 5 min washes with TBS containing 0.1% v/v Triton X-100. The membranes were then blocked again with the initial blocking solution for 1 hr and then incubated with peroxidase-conjugated rabbit anti-sheep antibody diluted 1:5000 for 1 hr, followed by three 5 min washes with TBS containing 0.1% v/v Triton X-100. Proteins were visualized using chemiluminescence followed by exposure to autoradiography film. Immunoblots were analyzed using MCID Elite software (InterFocus Imaging Ltd., Linton, UK), and the relative density of each band was expressed as arbitrary density units after subtracting background.

Isolation, cDNA synthesis and mRNA quantification. Liver tissue (50-100 mg) was homogenized in TRIzol reagent (Invitrogen) and total RNA was isolated according to the TRIzol reagent protocol. RNA concentrations were determined spectrophotometrically and total RNA integrity was confirmed by electrophoresis on a 1.2% agarose gel (OnBio, ON, Canada) stained

DMD # 40378

with ethidium bromide and inspection of the 28S and 18S ribosomal bands. cDNA was synthesized using 1 µg of total RNA, random hexamers (Invitrogen), RiboLock RNase inhibitor (Fermentas, Burlington, ON) and MMLV Reverse Transcriptase (Invitrogen) according to protocols provided by the manufacturers. Primers for real-time PCR amplification of CYP2E1 and β -actin were as follows: CYP2E1 forward primer (CYP2E1ex1): 5'-CCG CTT CCC ATC ATC GGG AAC-3', CYP2E1 reverse primer (CYP2E1ex1): 5'-GCG CTT TCA CCG CCT TGT A-3', β -actin forward primer (ACTBFex3): 5'-CAG AGC AAG AGA GGC ATC CT- 3', β -actin reverse primer (ACTBRex4/): 5'-GGT CTC AAA CAT GAT CTG GGT C-3'. The sequence of CYP2E1 in African Green monkey is not known; primer specificity was based on human CYP2E1 and Rhesus Macaque (*Macaca mulatta*) CYP2E1. Amplification and fluorescence detection were performed using the ABI ViiA7 Real-Time PCR system (Life Technologies). Real-time PCR amplification mixture (20 µl) contained 1 µl of synthesized cDNA, 10 µl of 2× Fast SYBR-Green Mix (Life Technologies), and 0.3 µM of each primer. Cycling conditions consisted of an initial activation of AmpliTaq Fast DNA polymerase followed by 40 cycles of denaturing (95°C for 15 s) and annealing/extension (58°C for 20s). Dilutions of monkey and human cDNA were used to determine the range of log linear detection. CYP2E1 mRNA levels were obtained by normalized to β -actin and using the comparative CT method for relative quantification as described by the manufacturer (Real-Time PCR Chemistry Guide, Life Technologies)

Statistics. Differences in alcohol (or sucrose) consumption and BEL were assessed by one-tailed Student's t-test, unpaired tests for between group comparisons and paired tests for within group comparisons. All pharmacokinetic statistical analyses were performed using SAS software

DMD # 40378

version 8.2 (SAS Institute, Cary, NC). One-tailed paired Student's t-tests were used to assess differences in *in vivo* CZN pharmacokinetic parameters measured pre and post-drug administration. One-tailed unpaired Student's t-test was used to compare the change in CZN AUC_{0-6hr} among groups. One-way ANOVA followed by post-hoc tests (Kruskal Wallis and test for linear trend) were used to determine differences in CYP2E1 protein levels, mRNA levels and *in vitro* CZN metabolism between groups. Correlations were calculated with Pearson correlation coefficients.

DMD # 40378

RESULTS

Monkeys Voluntarily Self-Administered Ethanol.

Monkeys consistently self-administered high levels of 10% ethanol throughout the study (Fig. 2A). Mean daily ethanol consumption during the four hour sessions in phases II and III ranged from 23.6-54.6 ml/kg (1.9-4.4g ethanol/kg), resulting in average consumption of 38.12 ± 7.8 ml/kg (3.0g of ethanol/kg). A gradual increase in mean daily ethanol consumption was observed as monkeys progressed from phase II to phase III of the study. This increase was statistically significant for both the ethanol-only ($p < 0.001$) and the ethanol + nicotine groups ($p = 0.04$) (Table 1). There was no significant difference in mean ethanol consumption between the ethanol-only and the ethanol + nicotine groups (Phase III, Table 1), indicating no effect of nicotine treatment on voluntary alcohol consumption. Sucrose consumption remained constant throughout the study.

Considerable individual variation in alcohol intake was observed. Monkeys were divided into high and low ethanol consumers by performing a median split based on mean daily consumption of ethanol during phase II and II (Fig. 2B and Table 1).

Blood ethanol levels (BEL) were measured on two occasions, once during phase II (day 38) and again during phase III (day 59). A paired-test reveals no significant difference in BEL measured during phase II and phase III for either the ethanol-only and ethanol + nicotine groups or for the high and low consumer groups, despite increases in ethanol consumption (Table 1).

In Vivo CZN Disposition is Influenced by Nicotine Treatment and the Level of Daily Ethanol Intake

DMD # 40378

A within animals design was used to assess changes in *in vivo* CZN metabolism due to animal variation in CZN pharmacokinetics. A comparison of *in vivo* CZN metabolism pre- and post-drug administration indicated that the nicotine-only group had a 34% decrease in CZN area under the curve (AUC) ($p=0.002$) and a 42% reduction in the maximum plasma CZN concentration (C_{\max}) ($p<0.001$) compared to before treatment (Table 2). Mean values for all the assessed CZN pharmacokinetic parameters were not significantly altered in the ethanol-only group, however, several monkeys showed a substantially decreased CZN AUC after ethanol self-administration (Fig. 3). In the ethanol + nicotine group there was a significant reduction in CZN AUC by 27% ($p=0.02$), C_{\max} by 35% ($p=0.003$) and the time to maximum CZN concentration (T_{\max}) by 35% ($p=0.04$). Kinetic parameters were not significantly different between groups pre-drug administration (day 22) and control monkeys (group 1) did not show significant changes in CZN pharmacokinetic parameters assessed on day 22 compared to day 50 (Supplemental Fig. 1).

There was a significant correlation between post-ethanol CZN AUC_{0-6h} and mean daily consumption of 10 % ethanol ($r = 0.42$, $p = 0.03$) (Fig. 4A). The high ethanol consumers had a post-ethanol CZN AUC_{0-6h} of 34 h. μ g/ml, which was significantly lower than the CZN AUC_{0-6h} of 64 h. μ g/ml seen in the low consumers ($p<0.05$) (Fig. 4B). Only in the high consumer group was there a significant change in CZN AUC post ethanol consumption ($p<0.05$) (Fig. 4C). Taken together, these results show a reduction in CZN AUC by ethanol that is dependent on the level of intake.

Hepatic CYP2E1 Protein Levels are Induced by Ethanol and Nicotine, Particularly when Both Drugs are Present in Combination and at Higher Ethanol Intakes

DMD # 40378

An immunoblotting assay was established to measure CYP2E1 protein levels in monkey liver. Detection of CYP2E1 in serially diluted liver microsomal protein from a control monkey was shown to be linear from 2-20 μg of protein (Fig. 5A). All subsequent immunoblots were loaded with 5 μg of microsomal protein. The CYP2E1 antibody did not cross-react with other cDNA-expressed human cytochromes P450 and monkey hepatic CYP2E1 co-migrated with cDNA-expressed human CYP2E1 (Fig. 5B).

Compared to control monkeys, ethanol self-administration alone resulted in a 56% increase in CYP2E1 levels ($p < 0.05$), nicotine treatment alone resulted in a 55% increase ($p < 0.05$), and combined ethanol self-administration and nicotine treatment resulted in a 106% increase ($p < 0.001$), suggesting an additive effect (Fig. 6A and 6B). Comparing mean CYP2E1 levels across all the groups, there is a significant linear trend; ethanol or nicotine exposure alone increased CYP2E1 levels compared to no drug exposure, and CYP2E1 levels were further increased with combined exposure to both drugs ($p_{\text{trend}} = 0.0002$). Ethanol and nicotine exposure, either alone or in combination, did not significantly alter CYP2E1 mRNA levels in the liver ($F(3, 33) = 2.423$, $p = 0.083$).

The effect of ethanol consumption level on CYP2E1 protein levels was also examined. High ethanol consumers had a 97% increase in CYP2E1 levels relative to control monkeys, while low consumers had a 65% increase. Comparing mean CYP2E1 levels among monkeys in the control, low ethanol consumer and high ethanol consumer groups, there was a significant linear trend, indicating increasing CYP2E1 protein levels with higher levels of ethanol consumption ($p_{\text{trend}} = 0.0004$) (Fig. 6C). CYP2E1 mRNA levels in the liver were not significantly different among the high consumer, low consumers or control animals ($F(2, 27) = 2.349$, $p = 0.1147$).

DMD # 40378

In Vitro CZN Metabolism is Induced by Ethanol and Nicotine, Particularly when Both Drugs are Present in Combination and at Higher Ethanol Intakes

The rate of CZN metabolism to 6OHCZN was measured *in vitro* using monkey liver microsomes. There was a significant positive correlation between hepatic CYP2E1 levels and *in vitro* 6OHCZN formation velocity at 950 μM (approximate V_{max}) ($r=0.45$ $p=0.002$) (Fig. 7A). Compared to control monkeys, ethanol self-administration alone and nicotine treatment alone resulted in an 11% increase in 6OHCZN formation velocity, although these increases were not significant after post-hoc testing ($p>0.05$) (Fig. 7B). Combined ethanol self-administration and nicotine treatment resulted in a 21% increase ($p<0.05$), suggesting an additive effect. Comparing mean CZN metabolism velocity across all the groups, there is a significant linear trend, with monkeys in the ethanol and nicotine combined group having the highest rate of CZN metabolism ($p_{\text{trend}}=0.003$).

The impact of ethanol consumption level on *in vitro* CZN metabolism was investigated. High ethanol consumers had a 19% increased in velocity of CZN metabolism compared control monkeys, whereas the low consumers had a 13% increase. Comparing mean CZN metabolism velocity among monkeys in the control, low ethanol consumer and high ethanol consumer groups, there was a significant linear trend, demonstrating that the rate of CZN metabolism increases with higher levels of ethanol consumption ($p_{\text{trend}}=0.003$) (Fig. 7C).

DMD # 40378

DISCUSSION

Humans and AGM have similar hepatic CYP2E1 levels, *in vivo* CZN disposition and *in vitro* CZN metabolism (Hayashi et al., 1991; Lee et al., 2006b), and while the AGM CYP2E1 has not been sequenced, both the cynomolgus monkey (*Macaca fascicularis*) and the rhesus monkey (*Macaca mulatta*), which are closely related to AGM, have a greater than 90% amino acid homology to human CYP2E1. Thus, AGM offer a valuable model for predicting the impact of ethanol and nicotine on CYP2E1 induction and metabolism in humans

Monkeys consistently self-administered high levels of ethanol throughout the study. Previous alcohol research classified AGM voluntarily self-administering between 0.8-3.5 g/kg ethanol/day as moderate consumers (Palmour et al., 1997). In our study, average daily ethanol intake was approximately 3.0 g/kg, identifying these monkeys as moderate consumers. Moderate alcohol consumption in humans has been described as intakes resulting in BEL ranging from 5-20 mmol/L (Eckardt et al., 1998). In our study, monkeys achieved an average BEL of 26 ± 2.55 mmol/L comparable to moderate consumption in humans; using BEL to compare ethanol consumption takes into consideration the two-fold greater rate of ethanol elimination in AGM compared to humans (Ervin et al., 1990).

Ethanol consumption steadily increased throughout the study, whereas BEL remained unchanged over time, suggesting increased rates of ethanol elimination in the monkeys. In humans, rats and other mammals ethanol metabolism is primarily mediated by alcohol dehydrogenase and to a lesser extent by CYP2E1 (Matsumoto et al., 1996; Lands, 1998). Human alcoholics have higher levels of CYP2E1, no change in alcohol dehydrogenase and an increased capacity to eliminate ethanol compared to non-alcoholics, suggesting that elevated CYP2E1 levels can affect ethanol metabolism (Vidal et al., 1990). Based on this premise, induction of

DMD # 40378

CYP2E1 in the ethanol-consuming monkeys may have contributed to metabolic tolerance, allowing monkeys to consume more ethanol without a corresponding rise in BEL.

Nicotine treatment did not affect voluntary consumption of 10% ethanol in AGM. Some studies in rats have shown an increase in ethanol consumption with chronic or repeated nicotine treatment while others have shown that nicotine treatment has no effect or even decreases ethanol consumption (Blomqvist et al., 1996; Le et al., 2000; Olausson et al., 2001; Sharpe and Samson, 2002). Differences in rats strains, methods used to initiate ethanol consumption and duration of the ethanol access period may contribute to the inconsistent results. A limited number of human studies have investigated the effect of nicotine on alcohol consumption. Occasional smokers (smoking an average of 10 cigarettes per week, and only smoking on two days per week) consumed more alcohol when smoking nicotine-containing cigarettes compared to denicotinized cigarettes (Barrett et al., 2006). A similar study in regular smokers (smoking more than 10 cigarettes per day) showed that smokers deprived of nicotine had a greater urge to consume alcohol compared to non-deprived smokers (Cooney et al., 2003). Therefore, the effect of nicotine on ethanol consumption in either rats or humans is complex and requires further investigation. Our study is the first to look at the effect of nicotine on voluntary ethanol self administration in monkeys where we observed no significant increase or decrease in ethanol consumption from the nicotine administration under the conditions tested.

Here we show that variation in ethanol intake, within the range of moderate drinking, can lead to very different CYP2E1 levels and activity as measured by CZN metabolism. High ethanol consuming monkeys were only drinking 25% more ethanol per day compared to the low consumers, however they demonstrated nearly a 50% greater reduction in post-ethanol CZN AUC *in vivo*. These results are interesting from a public health perspective, as our results

DMD # 40378

suggest that among moderate consumers those with higher daily ethanol intakes may be at elevated risk for CYP2E1 associated diseases.

The average smoker has a total daily nicotine intake of 0.2 to 1.1 mg/kg (Benowitz and Jacob, 1984) resulting in plasma levels of 10-50 ng/ml during the day (Benowitz NL, 1990). The total daily nicotine dose administered to the monkeys was at the high end of this range (1.0 mg/kg/day) to compensate for the slightly faster nicotine metabolism in AGM (Lee et al., 2006a). Although the pattern of nicotine intake in this study differs from smoking, the levels and duration of nicotine in the plasma were estimated to be comparable to what is observed in human smokers (Lee et al., 2006a, Benowitz NL, 1990). Nicotine increased CYP2E1 protein, CYP2E1 *in vitro* activity, and *in vivo* CZN clearance in the monkeys, consistent with the results of a previous study that assessed the effect of chronic nicotine treatment on CYP2E1 and CZN disposition in African Green monkeys (Lee et al., 2006b). The increase in CZN clearance following chronic nicotine exposure, without any change in CZN half-life, suggests that nicotine increases CZN first pass metabolism. It is unlikely that the change in CZN clearance could be attributed to nicotine's effect on blood flow. Monkeys were administered CZN more than 12 hr after the last nicotine injection, at which point any effect on hepatic blood flow would have subsided (Hashimoto et al., 2004). In humans, smoking increases CZN clearance by 25% (Benowitz et al., 2003). Nicotine-treated monkeys, similarly, showed a 34% decrease in CZN AUC, supporting a role for nicotine as the CYP2E1-inducing agent in cigarette smoke. Our results are not consistent with the conclusions from a recent study showing that administration of a 42-mg transdermal nicotine patch twice a day for 10 days did not affect CZN clearance in humans (Hukkanen et al., 2009). This discrepancy may be due to differences in the dose and

DMD # 40378

duration of nicotine achieved in the plasma with a transdermal nicotine patch versus smoking, which our study was designed to model.

There was a trend toward monkeys in the ethanol and nicotine combined group having the highest CYP2E1 protein levels and fastest rates of *in vitro* CZN metabolism compared to monkeys in either the ethanol-only or nicotine-only groups. This trend was not present in the *in vivo* CZN pharmacokinetic parameters, which may be due to the timing of the CZN pharmacokinetic testing. The post-drug CZN challenge was performed on day 50 and protein levels and *in vitro* activity were assessed in tissue from monkeys sacrificed on day 64. Ongoing induction of CYP2E1 by ethanol and nicotine may have occurred between days 50 and 64 of the study, resulting in a lack of correlation between *in vivo* and *ex vivo* assessment of CYP2E1 activity. In humans, moderate consumption of alcohol (40 g/day) over a period of four weeks resulted in a gradual increase in CYP2E1 activity measured by CZN clearance. CZN clearance was significantly faster on day 28 compared to day 21 (Oneta et al., 2002). In rats, 7 days of nicotine treatment is sufficient to induce CYP2E1 levels in the liver, however whether there is further induction of CYP2E1 beyond 7 days is not known (Joshi and Tyndale, 2006). Previously a correlation between *in vivo* CZN clearance and CYP2E1 protein levels was shown in nicotine-treated monkeys, however the duration between the *in vivo* and *ex vivo* testing was substantially shorter compared in this study (7 vs. 14 days) (Lee et al., 2006b).

Hepatic CYP2E1 mRNA levels were not significantly altered by nicotine or ethanol exposure, suggesting that, at these doses and durations of ethanol and nicotine exposure, induction of CYP2E1 protein occurs via a non-transcriptional mechanism. Consistent with our findings, ethanol-treated rats with BEL similar to our monkeys showed induction of hepatic CYP2E1 without a corresponding increase in CYP2E1 mRNA levels (Ronis et al., 1993).

DMD # 40378

Ethanol induces CYP2E1 protein levels in rats by protecting the enzyme from degradation (Roberts et al., 1995). Nicotine does not induce rat hepatic CYP2E1 via transcription or by protein stabilization and may involve an increase in translational efficiency (Wu et al., 1997; Micu et al., 2003). Thus ethanol and nicotine may increase CYP2E1 in monkey liver using similar post transcriptional mechanisms as observed for rat liver CYP2E1

In conclusion, ethanol and nicotine increased hepatic CYP2E1 protein and *in vitro* CZN metabolism leading to increased CZN clearance *in vivo*. The effect of ethanol was dependent on the level of daily ethanol intake and combined exposure to ethanol and nicotine resulted in the highest levels of hepatic CYP2E1 protein and activity. Nicotine treatment did not affect ethanol consumption. The induction of hepatic CYP2E1 by nicotine and ethanol may mediate some of the negative health effects of smoking and alcohol consumption via increased metabolic bioactivation of many commonly used industrial chemicals, environmental pollutants and drugs into toxic metabolites (Lieber, 1997). Since a large proportion of the population is exposed to ethanol, nicotine or often both, these findings have important implications for public health, health risk assessment and disease prevention.

DMD # 40378

ACKNOWLEDGMENTS

We thank Dr Bin Zhao and Ewa Hoffman for excellent technical assistance and Jibrán Khokhar for reviewing the manuscript.

DMD # 40378

AUTHORSHIP CONTRIBUTIONS

Participated in research design: Miksys, Palmour, Tyndale

Conducted experiments: Ferguson, Miksys, Palmour

Performed data analysis: Ferguson

Wrote or contributed to the writing of the manuscript: Ferguson, Tyndale

DMD # 40378

REFERENCES

- Amato G, Longo V, Mazzaccaro A and Gervasi PG (1998) Chlorzoxazone 6-hydroxylase and p-nitrophenol hydroxylase as the most suitable activities for assaying cytochrome P450 2E1 in cynomolgus monkey liver. *Drug Metab Dispos* **26**:483-489.
- Barrett SP, Tichauer M, Leyton M and Pihl RO (2006) Nicotine increases alcohol self-administration in non-dependent male smokers. *Drug Alcohol Depend* **81**:197-204.
- Benowitz NL and Jacob P, 3rd (1984) Daily intake of nicotine during cigarette smoking. *Clin Pharmacol Ther* **35**:499-504.
- Benowitz NL, Peng M and Jacob P, 3rd (2003) Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. *Clin Pharmacol Ther* **74**:468-474.
- Benowitz NL PH, and Jacob P 3rd (1990) *Pharmacokinetics, metabolism, and pharmacodynamics of nicotine, in Nicotine Psychopharmacology: Molecular, Cellular and Behavioral Aspects*. Oxford University Press, Oxford.
- Blomqvist O, Ericson M, Johnson DH, Engel JA and Soderpalm B (1996) Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. *Eur J Pharmacol* **314**:257-267.
- Caro AA and Cederbaum AI (2004) Oxidative stress, toxicology, and pharmacology of CYP2E1. *Annu Rev Pharmacol Toxicol* **44**:27-42.
- Cooney JL, Cooney NL, Pilkey DT, Kranzler HR and Oncken CA (2003) Effects of nicotine deprivation on urges to drink and smoke in alcoholic smokers. *Addiction* **98**:913-921.
- Eckardt MJ, File SE, Gessa GL, Grant KA, Guerri C, Hoffman PL, Kalant H, Koob GF, Li TK and Tabakoff B (1998) Effects of moderate alcohol consumption on the central nervous system. *Alcohol Clin Exp Res* **22**:998-1040.
- Ernstgard L, Warholm M and Johanson G (2004) Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. *Br J Clin Pharmacol* **58**:190-200.
- Ervin FR, Palmour RM, Young SN, Guzman-Flores C and Juarez J (1990) Voluntary consumption of beverage alcohol by vervet monkeys: population screening, descriptive behavior and biochemical measures. *Pharmacol Biochem Behav* **36**:367-373.
- Hashimoto T, Yoneda M, Shimada T, Kurosawa M and Terano A (2004) Intraportal nicotine infusion in rats decreases hepatic blood flow through endothelin-1 and both endothelin A and endothelin B receptors. *Toxicol Appl Pharmacol* **196**:1-10.
- Hayashi S, Watanabe J and Kawajiri K (1991) Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIIE1 gene. *J Biochem* **110**:559-565.
- Hukkanen J, Jacob Iii P, Peng M, Dempsey D and Benowitz NL (2009) Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. *Br J Clin Pharmacol* **69**:152-159.
- Ivester P, Roberts LJ, 2nd, Young T, Stafforini D, Vivian J, Lees C, Young J, Daunais J, Friedman D, Rippe RA, Parsons CJ, Grant KA and Cunningham C (2007) Ethanol self-administration and alterations in the livers of the cynomolgus monkey, *Macaca fascicularis*. *Alcohol Clin Exp Res* **31**:144-155.
- Joshi M and Tyndale RF (2006) Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. *Drug Metab Dispos* **34**:647-652.
- Lands WE (1998) A review of alcohol clearance in humans. *Alcohol* **15**:147-160.
- Le AD, Corrigan WA, Harding JW, Juzysch W and Li TK (2000) Involvement of nicotinic receptors in alcohol self-administration. *Alcohol Clin Exp Res* **24**:155-163.

DMD # 40378

- Leclercq I, Horsmans Y and Desager JP (1998) Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method. *J Chromatogr A* **828**:291-296.
- Lee AM, Miksys S, Palmour R and Tyndale RF (2006a) CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. *Neuropharmacology* **50**:441-450.
- Lee AM, Yue J and Tyndale RF (2006b) In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment. *Drug Metab Dispos* **34**:1508-1515.
- Lieber CS (1997) Cytochrome P-450E1: its physiological and pathological role. *Physiol Rev* **77**:517-544.
- Liu R, Yin LH and Pu YP (2007) Association of combined CYP2E1 gene polymorphism with the risk for esophageal squamous cell carcinoma in Huai'an population, China. *Chin Med J (Engl)* **120**:1797-1802.
- Matsumoto H, Matsubayashi K and Fukui Y (1996) Evidence that cytochrome P-450E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4-methyl pyrazole on ethanol elimination in the perfused rat liver. *Alcohol Clin Exp Res* **20**:12A-16A.
- Micu AL, Miksys S, Sellers EM, Koop DR and Tyndale RF (2003) Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. *J Pharmacol Exp Ther* **306**:941-947.
- Millonig G, Wang Y, Homann N, Bernhardt F, Qin H, Mueller S, Bartsch H and Seitz HK (2011) Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions. *Int J Cancer* **128**:533-540.
- Morita M, Le Marchand L, Kono S, Yin G, Toyomura K, Nagano J, Mizoue T, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Maekawa T, Yasunami Y, Takenaka K, Ichimiya H and Imaizumi N (2009) Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. *Cancer Epidemiol Biomarkers Prev* **18**:235-241.
- Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S and Katoh T (2003) Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. *J Cancer Res Clin Oncol* **129**:355-360.
- Olausson P, Ericson M, Lof E, Engel JA and Soderpalm B (2001) Nicotine-induced behavioral disinhibition and ethanol preference correlate after repeated nicotine treatment. *Eur J Pharmacol* **417**:117-123.
- Oneta CM, Lieber CS, Li J, Ruttimann S, Schmid B, Lattmann J, Rosman AS and Seitz HK (2002) Dynamics of cytochrome P450E1 activity in man: induction by ethanol and disappearance during withdrawal phase. *J Hepatol* **36**:47-52.
- Palmour RM, Mulligan J, Howbert JJ and Ervin F (1997) Of monkeys and men: vervets and the genetics of human-like behaviors. *Am J Hum Genet* **61**:481-488.
- Roberts BJ, Song BJ, Soh Y, Park SS and Shoaf SE (1995) Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. *J Biol Chem* **270**:29632-29635.
- Ronis MJ, Huang J, Crouch J, Mercado C, Irby D, Valentine CR, Lumpkin CK, Ingelman-Sundberg M and Badger TM (1993) Cytochrome P450 CYP 2E1 induction during

DMD # 40378

- chronic alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats. *J Pharmacol Exp Ther* **264**:944-950.
- Sharpe AL and Samson HH (2002) Repeated nicotine injections decrease operant ethanol self-administration. *Alcohol* **28**:1-7.
- Shiffman S. BM (1995) *Associations between alcohol and tobacco*. National Institute on Alcohol Abuse and Alcoholism Bethesda.
- Vidal F, Perez J, Morancho J, Pinto B and Richart C (1990) Hepatic alcohol dehydrogenase activity in alcoholic subjects with and without liver disease. *Gut* **31**:707-711.
- Wang W, Qiu YL, Ji F, Liu J, Wu F, Miao WB, Li Y, Brandt-Rauf PW and Xia ZL (2010) Genetic polymorphisms in metabolizing enzymes and susceptibility of chromosomal damage induced by vinyl chloride monomer in a Chinese worker population. *J Occup Environ Med* **52**:163-168.
- Wu D, Ramin SA and Cederbaum AI (1997) Effect of pyridine on the expression of cytochrome P450 isozymes in primary rat hepatocyte culture. *Mol Cell Biochem* **173**:103-111.
- Yue J, Khokhar J, Miksys S and Tyndale RF (2009) Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. *Eur J Pharmacol* **609**:88-95.
- Zhang Y, Liu Q, Liu Q, Duan H, Cheng J, Jiang S, Huang X, Leng S, He F and Zheng Y (2006) Association between metabolic gene polymorphisms and susceptibility to peripheral nerve damage in workers exposed to n-hexane: a preliminary study. *Biomarkers* **11**:61-69.

DMD # 40378

FOOTNOTES

This study was supported by the Centre for Addiction and Mental Health; Canadian Institute of Health Research [MOP97751]; Canadian Foundation for Innovation [20289 and 16014]; Ontario Ministry of Research and Innovation; Canada Research Chair in Pharmacogenetic to Dr. R.F. Tyndale; Canadian Liver Foundation and Scholarship Program for Interdisciplinary Capacity Enhancement. Dr. R.F. Tyndale has shares in Nicogen Research Inc. Funds were not received from Nicogen for these studies, nor was the manuscript reviewed by individuals associated with Nicogen

Reprint requests to:

Dr. Rachel F. Tyndale,
Department of Pharmacology and Toxicology
Rm 4326, 1 King's College Circle,
Toronto ON, Canada M5S 1A8
Email: r.tyndale@utoronto.ca

DMD # 40378

LEGENDS FOR FIGURES

Figure 1. Overview of the study timeline. Monkeys were randomized into four study groups (n=10 per group); Study groups consisted of a no-drug control group (group 1), an ethanol-only group (group 2), a nicotine-only group (group 3) and an ethanol + nicotine group (group 4). Groups were named based on drug exposure during the last phase of the study (phase III). Blood ethanol levels (BEL) were measured near the end of phase II and phase III. *In vivo* CZN metabolism was assessed during the washout period prior to phase II, and at the end of phase III. On day 50, nicotine treatment and alcohol access was suspended in order to conduct pharmacokinetic testing.

Figure 2. Monkeys voluntarily self-administered ethanol. A) Average daily consumption by monkeys self-administering alcohol in sucrose (squares) or sucrose alone (circles). Phase I is the ethanol preference screening period (consumption levels at screening represent average consumption during this phase). During phase II monkeys in the ethanol-only (group 2) and ethanol + nicotine (group 4) groups self-administered ethanol in sucrose solution while the other groups (1 and 3) consumed sucrose solution only on the same schedule. During Phase III in addition to alcohol (or sucrose), monkeys in the in the nicotine-only (group 3) and ethanol + nicotine (group 4) groups were given nicotine injections while monkeys in the other groups (1 and 2) were give saline injections on the same schedule. B) A median split was used to categorize monkeys into low and high ethanol consumers based on mean daily consumption of 10% ethanol during phase II and III. B) Unfilled symbols represent monkeys in ethanol-only

DMD # 40378

group (group 2), filled symbol represent monkeys in the ethanol + nicotine group (group 4) and horizontal lines indicated group means. Significantly different from low consumers, * $p < 0.05$.

Figure 3. Ethanol self-administration and nicotine treatment reduced chlorzoxazone AUC. A) Mean CZN plasma concentration over time curves for treatment groups, $n=10$ per group. B) Lines represent the change in plasma CZN AUC_{0-6hr} for individual monkeys pre-drug administration (day 22) and post-drug administration (day 50). Diamonds with error bars represent mean $AUC_{0-6hr} \pm SE$ for the group pre- and post drug administration; for the ethanol-only group, the filled diamonds indicate the mean including the monkey with a noticeably high CZN AUC_{0-6hr} both pre- and post-ethanol exposure (indicated by the dashed line) and the unfilled diamonds indicate the mean excluding this monkey. Significantly different from same group of monkeys pre-drug administration, * $p < 0.05$.

Figure 4. Correlation between ethanol consumption and chlorzoxazone AUC. A) There was a significant negative correlation between mean consumption of 10% ethanol (ml/kg/day) during phase II and II and CZN AUC_{0-6hr} post-drug administration (day 50). With the exclusion of the monkey with noticeably high post-ethanol CZN AUC (circled), the correlation remains significant ($r=0.43$, $p=0.04$). B) High ethanol consumers (see fig 2B) had a significantly reduced CZN AUC_{0-6hr} compared low consumers ($p < 0.05$), $n=10$ per group. C) Lines represent the change in plasma CZN AUC_{0-6hr} for high or low ethanol consumers pre-drug administration (day 22) and post-drug administration (day 50). Diamonds with error bars represent mean $AUC_{0-6hr} \pm SE$ for the group pre- and post drug administration with (filled) or without (unfilled) the inclusion of a monkey with a noticeably high CZN AUC_{0-6hr} both pre- and post-ethanol exposure

DMD # 40378

(indicated by the dashed line). Significantly different from same group of monkeys pre-drug administration, * $p < 0.05$.

Figure 5. Detection of CYP2E1 monkey hepatic protein was linear and specific. A) A dilution curve of monkey hepatic microsomal protein showed linear detection of CYP2E1 from 2-20 μg . B) The anti-CYP2E1 antibody used for the CYP2E1 immunoblotting did not cross react with cDNA-expressed human CYP2A6, CYP2A1, CYP1A2, CYP2D6, CYP3A4, CYP2B6. Monkey hepatic CYP2E1 co-migrated with cDNA-expressed human CYP2E1.

Figure 6. Ethanol self-administration and nicotine treatment, alone and in combination, induced hepatic CYP2E1 protein levels. A) Representative immunoblot for hepatic CYP2E1 protein from monkeys in the four study groups (showing $n = 4$ of 10 per group). Coomassie blue staining was used to confirm equal protein loading among lanes. B) Mean percent increase in CYP2E1 protein relative to control group. A significant linear trend was observed, with animals in the ethanol + nicotine group (group 4) having the highest levels of CYP2E1. Significantly different from control group, * $p < 0.05$, ** $p < 0.001$. $n = 10$ per group. C) Mean percent increase in hepatic CYP2E1 protein in high and low ethanol consumers (see Fig. 2B) relative to control group. A significant linear trend was observed, demonstrating increased CYP2E1 levels with higher levels of alcohol consumption. Significantly different from control group, * $p < 0.05$, ** $p < 0.001$. $n = 10$ for each group.

Figure 7. Ethanol self-administration and nicotine treatment increased *in vitro* chlorzoxazone metabolism. A) Hepatic CYP2E1 protein levels were positively correlated with 6OHCZN

DMD # 40378

formation velocity at 950 μM CZN (approximate v_{max}). B) Mean percent increases in the 6OHCZN formation velocity relative to the control group. A significant linear trend was observed, with animals in the ethanol + nicotine group (group 4) having the highest velocity. Significantly different from control group, $*p<0.05$. $n=10$ per group. C) Mean percent increases in velocity of CZN metabolism in high and low ethanol consumers (see Fig 2B.) relative to the control group. A significant linear trend was observed, demonstrating increased CZN velocity with higher levels of alcohol consumption. Significantly different from control group, $*p<0.05$. $n=10$ for each group.

DMD # 40378

Table I. Consumption of 10% ethanol increase over time with no increase in blood ethanol levels (values expressed as mean \pm SE, n=10/group)

	Phase II		Phase III	
	Consumption (ml/kg/day)	BEL (mmol/L)	Consumption (ml/kg/day)	BEL (mmol/L)
Group 3: EtOH-only	35.4 \pm 1.2	24.6 \pm 3.9	42.4 \pm 1.9*	26.3 \pm 9.3
Group 4: EtOH + Nicotine	37.8 \pm 2.2	23.8 \pm 2.1	40.7 \pm 3.1*	29.7 \pm 4.7
Low consumers	32.9 \pm 1.6	22.9 \pm 3.8	35.5 \pm 1.6*	24.7 \pm 4.0
High consumers	37.3 \pm 1.6 [†]	25.5 \pm 2.2	45.1 \pm 1.9* [‡]	31.7 \pm 4.0

Consumption and BEL were not significantly different between groups during either phase

*p<0.05, significantly different from phase II

[†]p<0.05, [‡]p<0.001, significantly different from low consumer

DMD # 40378

Table II. Kinetic parameters (mean \pm SE, n=10) from CZN pre-drug administration (day 22) and post drug administration (day 50)

CZN	<u>Pre-EtOH</u>	<u>Post-EtOH</u>	<u>Pre-nicotine</u>	<u>Post-nicotine</u>	<u>Pre-EtOH + nicotine</u>	<u>Post-EtOH + nicotine</u>
AUC (hr.ug/ml)	54.8 \pm 7.9	56.6 \pm 13.6	44.8 \pm 6.2	29.5 \pm 5.6*	56.8 \pm 4.6	41.6 \pm 3.2*
Cmax (ug/ml)	17.5 \pm 2.7	27.7 \pm 5.7	20.2 \pm 3.6	11.7 \pm 2.5*	25.3 \pm 3.0	16.4 \pm 2.0*
tmax (hr)	1.3 \pm 0.2	0.9 \pm 0.2	1.1 \pm 0.2	1.3 \pm 0.2	1.1 \pm 0.2	0.7 \pm 0.1*
t1/2 (hr)	1.3 \pm 0.1	1.2 \pm 0.1	0.9 \pm 0.1	1.1 \pm 0.1	1.0 \pm 0.1	1.8 \pm 0.3

Kinetic parameters were not significantly different between groups pre-drug administration

*p<0.05, significantly different from pre-drug administration within the same treatment group

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

